Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

John M. Lachin; Giancarlo Viberti; Bernard Zinman; Steven M. Haffner; R. Paul Aftring; Gitanjali Paul; Barbara G. Kravitz; William H. Herman; Rury R. Holman; Steven E. Kahn

doi:10.2215/CJN.09291010

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

John M. Lachin, Giancarlo Viberti, Bernard Zinman, Steven M. Haffner, R. Paul Aftring, Gitanjali Paul, Barbara G. Kravitz, William H. Herman, Rury R. Holman, Steven E. Kahn

King's College London

Research output: Contribution to journal › Article › peer-review

71 Citations (Scopus)

Abstract

Background and objectives In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups. Design, setting, participants, & measurements A total of 4351 recently diagnosed, drug-naive patients with type 2 diabetes were treated and followed for up to 5 years with rosiglitazone, metformin, or glyburide and were examined with periodic assessments of albumin/creatinine ratio (ACR), modification of diet in renal disease (MDRD)-estimated GFR, and BP. Results The ACR rose slowly with metformin. It fell with rosiglitazone and less so with glyburide over the first 2 years, and then rose slowly over time. Estimated GFR (eGFR) with all therapies rose into the high normal range over the first 3 to 4 years, more so with rosiglitazone, and then declined, more so with glyburide. Systolic BP was stable over time, values with rosiglitazone being lower, and diastolic BP declined over time, more so with rosiglitazone than with metformin or glyburide. There was no difference among groups in the incidence of emergent albuminuria (ACR >= 30 mg/g), hypertension, or impaired eGFR (

Original language	English
Pages (from-to)	1032 - 1040
Number of pages	9
Journal	Journal of the American Society of Nephrology
Volume	6
Issue number	5
DOIs	https://doi.org/10.2215/CJN.09291010
Publication status	Published - 1 May 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2215/CJN.09291010

Cite this

@article{8c5f3e4e7c0a4743a5043dcaa398e024,

title = "Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy",

abstract = "Background and objectives In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups. Design, setting, participants, & measurements A total of 4351 recently diagnosed, drug-naive patients with type 2 diabetes were treated and followed for up to 5 years with rosiglitazone, metformin, or glyburide and were examined with periodic assessments of albumin/creatinine ratio (ACR), modification of diet in renal disease (MDRD)-estimated GFR, and BP. Results The ACR rose slowly with metformin. It fell with rosiglitazone and less so with glyburide over the first 2 years, and then rose slowly over time. Estimated GFR (eGFR) with all therapies rose into the high normal range over the first 3 to 4 years, more so with rosiglitazone, and then declined, more so with glyburide. Systolic BP was stable over time, values with rosiglitazone being lower, and diastolic BP declined over time, more so with rosiglitazone than with metformin or glyburide. There was no difference among groups in the incidence of emergent albuminuria (ACR >= 30 mg/g), hypertension, or impaired eGFR (",

author = "Lachin, {John M.} and Giancarlo Viberti and Bernard Zinman and Haffner, {Steven M.} and Aftring, {R. Paul} and Gitanjali Paul and Kravitz, {Barbara G.} and Herman, {William H.} and Holman, {Rury R.} and Kahn, {Steven E.}",

year = "2011",

month = may,

day = "1",

doi = "10.2215/CJN.09291010",

language = "English",

volume = "6",

pages = "1032 -- 1040",

journal = "Journal of the American Society of Nephrology",

issn = "1555-905X",

publisher = "American Society of Nephrology",

number = "5",

}

TY - JOUR

T1 - Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

AU - Lachin, John M.

AU - Viberti, Giancarlo

AU - Zinman, Bernard

AU - Haffner, Steven M.

AU - Aftring, R. Paul

AU - Paul, Gitanjali

AU - Kravitz, Barbara G.

AU - Herman, William H.

AU - Holman, Rury R.

AU - Kahn, Steven E.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background and objectives In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups. Design, setting, participants, & measurements A total of 4351 recently diagnosed, drug-naive patients with type 2 diabetes were treated and followed for up to 5 years with rosiglitazone, metformin, or glyburide and were examined with periodic assessments of albumin/creatinine ratio (ACR), modification of diet in renal disease (MDRD)-estimated GFR, and BP. Results The ACR rose slowly with metformin. It fell with rosiglitazone and less so with glyburide over the first 2 years, and then rose slowly over time. Estimated GFR (eGFR) with all therapies rose into the high normal range over the first 3 to 4 years, more so with rosiglitazone, and then declined, more so with glyburide. Systolic BP was stable over time, values with rosiglitazone being lower, and diastolic BP declined over time, more so with rosiglitazone than with metformin or glyburide. There was no difference among groups in the incidence of emergent albuminuria (ACR >= 30 mg/g), hypertension, or impaired eGFR (

AB - Background and objectives In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, renal function (estimated GFR), and BP over 5 years between treatment groups. Design, setting, participants, & measurements A total of 4351 recently diagnosed, drug-naive patients with type 2 diabetes were treated and followed for up to 5 years with rosiglitazone, metformin, or glyburide and were examined with periodic assessments of albumin/creatinine ratio (ACR), modification of diet in renal disease (MDRD)-estimated GFR, and BP. Results The ACR rose slowly with metformin. It fell with rosiglitazone and less so with glyburide over the first 2 years, and then rose slowly over time. Estimated GFR (eGFR) with all therapies rose into the high normal range over the first 3 to 4 years, more so with rosiglitazone, and then declined, more so with glyburide. Systolic BP was stable over time, values with rosiglitazone being lower, and diastolic BP declined over time, more so with rosiglitazone than with metformin or glyburide. There was no difference among groups in the incidence of emergent albuminuria (ACR >= 30 mg/g), hypertension, or impaired eGFR (

U2 - 10.2215/CJN.09291010

DO - 10.2215/CJN.09291010

M3 - Article

SN - 1555-905X

VL - 6

SP - 1032

EP - 1040

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

IS - 5

ER -

Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this